Strattera

Strattera

atomoxetine

Manufacturer:

Eli Lilly

Distributor:

DKSH
Concise Prescribing Info
Contents
Atomoxetine HCl
Indications/Uses
ADHD in childn ≥6 yr, adolescents & adults.
Dosage/Direction for Use
Adult, adolescent & childn >70 kg Initiate at a total daily dose of 40 mg & increased after a min of 3 days to approx 80 mg. Dose may be increased after 2-4 additional wk to a max of 100 mg. Adolescent & childn up to 70 kg Initiate at a total daily dose of 0.5 mg/kg & increased after a min of 3 days to 1.2 mg/kg. Dose may be increased after 2-4 additional wk to a max of 1.4 mg/kg or 100 mg, whichever is less. Patient w/ moderate hepatic impairment Initial & target doses should be reduced to 50% of the normal dose. Patient w/ severe hepatic impairment Initial & target doses should be reduced to 25% of the normal dose. Adult, adolescent & childn >70 kg administered w/ strong CYP2D6 inhibitors Initiate at 40 mg/kg/day & only increase to 80 mg/day. Adolescent & childn up to 70 kg administered w/ strong CYP2D6 inhibitors Initiate at 0.5 mg/kg/day & only increased to 1.2 mg/kg/day.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Symptomatic CV disease (ie, moderate to severe HTN; atrial fibrillation & flutter; ventricular tachycardia, fibrillation & flutter; advanced arteriosclerosis. Severe cardiac or vascular disorders. Uncontrolled hyperthyroidism. Existing or history of phaeochromocytoma. Concurrent use w/ MAOI. Narrow angle glaucoma.
Special Precautions
Monitor for suicidal ideation & behaviour in childn & adolescents, appearance or worsening of aggressive behaviour or hostility. Possible allergic events. Patients w/ history of seizures. Measure heart rate & BP prior to treatment, after the dose is increased or decreased & periodically during treatment. Patients w/ HTN, tachycardia, CV or cerebrovascular disease, congenital, acquired, or has a family history of QT prolongation, any condition that may predispose patients to orthostatic hypotension or conditions associated w/ abrupt heart rate or BP changes. Not to be used in patients w/ severe CV disorders whose condition would be expected to deteriorate, w/ known structural cardiac abnormalities. Increased risk of sudden/cardiac death. Patients w/ enlarged prostates or conditions predisposing to urinary retention. Seek prompt medical attention if priapism is suspected. Periodic monitoring of height & wt for patients requiring long-term therapy. Discontinue in patients w/ jaundice or laboratory evidence of liver injury. Hepatic & renal impairment. May affect the ability to drive or operate machinery. Pregnancy & lactation. Childn <6 yr. Elderly >65 yr.
Adverse Reactions
Dry mouth, nausea, increased BP, heart rate & wt, decreased appetite, headache, decreased libido; abdominal pain, vomiting, somnolence.
Drug Interactions
Increase plasma exposure w/ CYP2D6 inhibitors (ie, fluoxetine, paroxetine & quinidine). Contraindicated w/ MAOIs. Possible effects on BP w/ antihypertensive & pressor agents. Potential additive or synergistic effects w/ drugs that affect noradrenaline (eg, α1 agonists). Potentiation of CV effects w/ salbutamol or other β2-agonists. Potential increase in CV effects w/ TCAs (ie, despiramine). Increased fraction of unbound drugs (ie, diazepam, paroxetine & phenytoin).
ATC Classification
N06BA09 - atomoxetine ; Belongs to the class of centrally-acting sympathomimetics. Used as CNS stimulant.
Presentation/Packing
Form
Strattera cap 10 mg
Packing/Price
28's
Form
Strattera cap 40 mg
Packing/Price
28's
Form
Strattera cap 60 mg
Packing/Price
28's
Form
Strattera cap 18 mg
Packing/Price
28's
Form
Strattera cap 25 mg
Packing/Price
28's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in